| Number: CTEP 8762 |
Principal Investigator: Ma, Cynthia |
| Title: A Phase 1 Trial of MK-2206 in Combination with Anastrozole, Fulvestrant, or Anastrozole plus Fulvestrant in Postmenopausal Women with Estrogen Receptor Positive Metastatic Breast Cancer |
| Description: The purpose of this research study is to find out what effects, good and/or bad, the drug MK-2206 has on patients and their metastatic breast cancer when given in combination with hormonal therapy (anastrozole or letrozole), which blocks or limits the production of estrogen, which estrogen receptor-...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201301106 |
Principal Investigator: Ma, Cynthia |
| Title: Phase II Trial of Neoadjuvant PD 0332991, a Cyclin-Dependent Kinase (CDK) 4/6 inhibitor, in Combination with Anastrozole in Postmenopausal Women with Clinical Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer |
| Description: The purpose of this research study is to find out what efects, good and/or bad, the drug PD 0332991 in combination with anastrozole (with or without goserelin) has on the patinet and their breast cancer....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201209135 |
Principal Investigator: Ma, Cynthia |
| Title: A Phase II Study of Neratinib in Metastatic HER2 Non-amplified but HER2 Mutant Breast Cancer |
| Description: This phase II study will test cancer to see if it has a HER2 mutation and, if so, see how HER2 mutated cancer responds to treatment with neratinib....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201106403 |
Principal Investigator: Zoberi, Imran |
| Title: Intensity Modulated Radiation Therapy for Breast Cancer: A Phase I Feasibility Study |
| Description: The purpose of this study is to find out about the effectiveness and safety of a new way of delivering radiation therapy. Standard treatment for you cancer includes radiation therapy. In this study we will give you radiation therapy through a system called Intensity Modulated Radiation Therapy. I...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201106141 |
Principal Investigator: Pluard, Timothy |
| Title: A Multisite International Collaborative Phase 2 Study of Neoadjuvant Goserelin and a Non-steroidal Aromatase Inhibitor for Premenopausal Women with Estrogen Receptor Positive HER2 Negative Clinical Stage 2 and 3 Breast Cancer |
| Description: The purpose of this research study is to see whether these patients would benefit from endocrine therapy alone or whether they should be offered a chemotherapy regimen as part of their treatment....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201105445 |
Principal Investigator: Ma, Cynthia |
| Title: A phase 1 trial of BKM 120, a novel oral selective phosphatidylinositol-3-kinase (PI3K) inhibitor, in combination with fulvestrant in postmenopausal women with estrogen receptor positive metastatic breast cancer |
| Description: The purpose of this research study is to learn about the safety of BKM120 and fulvestrant when the two drugs are given together, to see what effects the combination of BKM120 and fulvestrant has on the body and on tumors, and to determine the highest safest dose of BKM120 that can be given in combin...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201011731 |
Principal Investigator: Aft, Rebecca |
| Title: Effect of Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer: Clinical Outcome and Correlation to Biological Parameters |
| Description: The purpose of this study is to determine whether platinum-based chemotherapy (either cisplatin or carboplatin), when given with radiation therapy prior to surgery, is effective in improving response to
treatment in triple negative breast cancer patients. This treatment is being studied in this typ...MORE |
| ___________________________________________________________________________________________________ |
| Number: P2C 9170 |
Principal Investigator: Ma, Cynthia |
| Title: A Phase II Trial of Neoadjuvant MK-2206 in Combination with either Anastrozole if Postmenopausal or Anastrozole and Goserelin if Premenopausal in Women with Clinical Stage 2 or 3 PIK3CA Mutant Estrogen Receptor Positive and HER2 Negative Invasive Breast Cancer |
| Description: The purpose of this research study is to find out what effects, good and/or bad, the drug MK-2206 in combination with anastrozole with or without goserelin (depending on menopausal status) has on patients and their breast cancer....MORE |
| ___________________________________________________________________________________________________ |
| Number: HOG BRE09-146 |
Principal Investigator: Ma, Cynthia |
| Title: PARP Inhibition after Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer or ER/PR +, HER2 negative with known BRCA1/2 Mutations |
| Description: The purpose of this study is to test a new cancer treatment drug called PF-01367338 in combination with cisplatin to see what effects (good and bad) it has on patients and their breast cancer....MORE |
| ___________________________________________________________________________________________________ |
| Number: RTOG 1119 |
Principal Investigator: Zoberi, Imran |
| Title: Phase II Randomized Study of Whole Brain Radiotherapy in Combination with Concurrent Lapatinib in Patients with Brain Metastasis from Her2-Positive Breast Cancer A Collaborative Study of RTOG and KROG |
| Description: The purpose of this research study is to compare the effects of adding lapatinib to standard whole brain radiation therapy (WBRT) on you and your cancer. The study will try to find out whether WBRT or lapatinib plus WBRT is better at safely improving tumor control. In this study, you will receive ei...MORE |
| ___________________________________________________________________________________________________ |
| Number: RTOG 1014 |
Principal Investigator: Zoberi, Imran |
| Title: A Phase II Study of Repeat Breast Preserving Surgery and 3D-Conformal Partial Breast Re-Irradiation (PBrI) for Local Recurrence of Breast Carcinoma
|
| Description: The purpose of this study is to evaluate the side effects of partial breast re-irradiation given after a lumpectomy. The lumpectomy will remove the breast cancer and a limited amount of surrounding normal breast tissue. Following the surgery, you will receive three dimensional conformal radiation th...MORE |
| ___________________________________________________________________________________________________ |
| Number: RTOG 1005 |
Principal Investigator: Zoberi, Imran |
| Title: A Phase III Trial of Accelerated Whole Breast Irradiation with Hypofractionation Plus Concurrent Boost versus Standard Whole Breast Irradiation plus Sequential Boost for Early-Stage Breast Cancer |
| Description: The purpose of this study is to compare radiation therapy given with a higher daily dose over 3 weeks with a boost given each day of radiation therapy compared with standard whole breast radiation followed by a boost given on separate days which extends over 6 to 6 ½ weeks. It is not expected that t...MORE |
| ___________________________________________________________________________________________________ |
| Number: CTSU S1007 |
Principal Investigator: Naughton, Michael |
| Title: A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) OF 25 or Less |
| Description: Currently many women with breast cancer are treated with endocrine therapy. Many women also receive chemotherapy. No one really knows which patients with lower Recurrence Scores need to get chemotherapy. Some women may be getting chemotherapy who do not need it. These women may be exposed to sid...MORE |
| ___________________________________________________________________________________________________ |
| Number: CTSU NSABP B-49 |
Principal Investigator: Naughton, Michael |
| Title: A Phase III Clinical Trial Comparing the Combination of Docetaxel plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer |
| Description: This randomized phase III trial is studying different combination chemotherapy regimens and their side effects and comparing how well they work in treating women with non-metastatic breast cancer....MORE |
| ___________________________________________________________________________________________________ |
| Number: CTSU E2108 |
Principal Investigator: Margenthaler, Julie |
| Title: A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer |
| Description: We do not know if local (i.e. surgery and/or radiation) treatment of the tumor of the breast will help patients with metastatic breast cancer live longer or not. The purpose of this study is to compare the good and bad effects of a new approach that includes surgery plus radiation to the standard a...MORE |
| ___________________________________________________________________________________________________ |
| Number: CTSU B-43 |
Principal Investigator: Zoberi, Imran |
| Title: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive
Ductal Carcinoma In Situ Resected by Lumpectomy
|
| Description: This study is being done to compare the effects, good and/or bad, of adding the drug trastuzumab (also called Herceptin®) to breast radiation therapy. Radiation therapy is the standard treatment for patients with DCIS. This study will find out if adding trastuzumab to breast radiation therapy is mor...MORE |
| ___________________________________________________________________________________________________ |
| Number: CALGB NSABP B-47 |
Principal Investigator: Pluard, Timothy |
| Title: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer |
| Description: The main purpose of this study is to learn if adding a targeted therapy, trastuzumab (Herceptin), to standard treatment with chemotherapy for early stage, HER2-low breast cancer, will prevent breast cancer from returning....MORE |
| ___________________________________________________________________________________________________ |
| Number: CALGB 8129 |
Principal Investigator: Ma, Cynthia |
| Title: Phase I/II trial of IMC-A12 in combination with Temsirolimus in patients with metastatic breast cancer |
| Description: This phase I/II trial is studying the side effects and best dose of IMC-A12 when given together with temsirolimus and to see how well they work in treating patients with locally recurrent or metastatic breast cancer....MORE |
| ___________________________________________________________________________________________________ |
| Number: ACOSOG Z11102 |
Principal Investigator: Margenthaler, Julie |
| Title: Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients with Multiple Ipsilateral Breast Cancers (MIBC) (Z11102) |
| Description: The purpose of this research study is to see if removing only the tissues from the 2 or 3 cancers in your breast (breast conservation surgery) in combination with radiation to the breast, instead of removing your entire breast (mastectomy) is safe in keeping your cancer from coming back in your brea...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201210085 |
Principal Investigator: Ma, Cynthia |
| Title: A phase III randomized, double blind, placebo controlled study of BKM120 with fulvestrant, in postmenopausal women with hormone receptor-positive HER2-negative AI treated, locally advanced or metastatic breast cancer who progressed on or after mTOR inhibitor based treatment |
| Description: The purpose of this trial is to see the safety and efficacy of fulvestrant with an investigational drug (BKM120) in patients with hormone receptor positive metastatic breast cancer that have recently progressed on a mTOR inhibitor (everlimous)....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201209119 |
Principal Investigator: Pluard, Timothy |
| Title: A randomized, double-blind, placebo controlled, phase II study of BKM120 plus paclitaxel in patients with HER2 negative inoperable locally advanced or metastatic breast cancer, with or without PI3K pathway activation |
| Description: The purpose of this study is to compare the benefit and the safety profile of a combination of the investigational treatment BKM120 plus paclitaxel against paclitaxel plus placebo in patients with locally advanced or metastatic breast cancer....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201209067 |
Principal Investigator: Ma, Cynthia |
| Title: A phase III randomized, double blind placebo controlled study of BKM120 with fulvestrant, in postmenopausal women with hormone receptor-positive HER2-negative locally advanced or metastatic breast cancer which progressed on or after aromatase inhibitor treatment |
| Description: The purpose of this trial is to see the safety and efficacy of fulvestrant with an investigational drug (BKM120) in patients with hormone receptor positive metastatic breast cancer that have recently progressed on an aromatase inhibitor (AI)....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201207087 |
Principal Investigator: Ellis, Matthew |
| Title: A Randomised, Double-blind, Parallel-group, Multicentre, Phase III Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEXTM) 500 mg with Anastrozole (ARIMIDEXTM) 1 mg as Hormonal treatment for Postmenopausal Women with Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Been Treated with Any Hormonal Therapy (FALCON) |
| Description: This research study measures the size of breast cancer tumors every 12 weeks and will help decide whether fulvestrant slows the growth of these tumors more than anastrozole....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201206061 |
Principal Investigator: Naughton, Michael |
| Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Bevacizumab, and Associated Biomarkers in Combination with Paclitaxel Compared with Paclitaxel plus Placebo as First-Line Treatment of Patients with HER2-Negative Metastatic Breast Cancer |
| Description: The purpose of this research study is to see which patients are most likely to benefit from treatment with bevacizumab by using a simple blood test and to understand how the combination of bevacizumab with paclitaxel may improve a patient's cancer diagnosis, delay the growth of their tumor(s), and s...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201205149 |
Principal Investigator: Pluard, Timothy |
| Title: The BEACON Study (BrEAst Cancer Outcomes with NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician’s Choice (TPC) in Patients with Locally Recurrent or Metastatic Breast Cancer Previously Treated with an Anthracycline, a Taxane, and Capecitabine
|
| Description: The purpose of this research study is to test whether NKTR-102 compared with standard treatment for breast cancer is safe and effective in treating patients with advanced breast cancer. This study will look at how cancer responds to the study treatment. It will also look at the side effects of NKTR-...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201205130 |
Principal Investigator: Pluard, Timothy |
| Title: A Two-Cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab given in Combination with Trastuzumab and Vinorelbine in First Line Patients with HER2-positive Advanced (metastatic or locally advanced) Breast Cancer |
| Description: The purpose of this research study is to compare the overall response rates of pertuzumab given in combination with trastuzumab in a single infusion bag followed by vinorelbine, versus giving pertuzumab, trastuzumab and vinorelbine given in separate infusion bags. The results of this study could mi...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201202149 |
Principal Investigator: Pluard, Timothy |
| Title: A randomized, two-arm, open-label, multicenter Phase II trial assessing the efficacy and safety of pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in first line patients with HER2-positive and hormone receptor-positive advanced (metastatic or locally advanced) breast cancer |
| Description: This study will evaluate the efficacy and safety of pertuzumab in combination with trastuzumab plus an aromatase inhibitor in patients with HER2-positive and hormone receptor-positive advanced breast cancer....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201111195 |
Principal Investigator: Pluard, Timothy |
| Title: A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer |
| Description: This study will assess the safety and efficacy of pertuzumab in addition to chemotherapy plus Herceptin as adjuvant therapy in patients with operable HER2-positive primary breast cancer....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201110186 |
Principal Investigator: Pluard, Timothy |
| Title: A Randomized Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination with Temozolomide or Veliparib in Combination with Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects with BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer |
| Description: The main purpose of the study is to determine if patients with metastatic breast cancer do better with veliparib in combination with temozolomide or carboplatin and paclitaxel with or without veliparib....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201110013 |
Principal Investigator: Ma, Cynthia |
| Title: A Phase II, Double-Blind, Placebo-Controlled, Randomized Study of GDC-0941 or GDC-0980 with Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy |
| Description: The purpose of this study is to find out what effects, good and/or bad, two drugs called GDC-0941 and GDC-0980 have on patients and their breast cancer when given in combination with another drug, called fulvestrant....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201104332 |
Principal Investigator: Pluard, Timothy |
| Title: A Phase Ib/II, open label, multi-center study evaluating the safety and efficacy of BKM120 in combination with trastuzumab in patients with relapsing HER2 overexpressing breast cancer who have previously failed trastuzumab |
| Description: The purpose of this study is to investigate new treatment options for patients with HER2 overexpressing locally advanced or metastatic breast cancer....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201012844 |
Principal Investigator: Zoberi, Imran |
| Title: A Phase I/II Study Evaluating the Maximum Tolerated Dose, Pharmacokinetics, Safety, and Efficacy of Hyperthermia and Thermodox (Lyso-Thermosensitive Liposomal Doxorubicin) in Patients with Breast Cancer Recurrence at the Chest Wall |
| Description: The purpose of this research study is to evaluate the effects of ThermoDox® in combination with therapeutic heating of the chest wall in the treatment of recurrent regional breast cancer. The United States Food and Drug Administration has approved therapeutic heat for the treatment of breast cancer...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201105084 |
Principal Investigator: Colditz, Graham |
| Title: Reducing Breast Cancer Recurrence with Weight Loss: A Vanguard Trial |
| Description: This study will investigate the capability of a weight loss program, involving nutrition and exercise interventions, the biological mechanisms that link obesity and lower survival rates and the impact of weight loss on quality of life in breast cancer survivors....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201111057 |
Principal Investigator: Dehdashti, Farrokh |
| Title: Positron Emission Tomography (PET) with 18F-Fluoroestradiol (FES) as a Predictor of Response in Patients with Breast Cancer Scheduled to be Treated with MK-2206 in Combination with Either an Aromatase Inhibitor or Fulvestrant on NCI Protocol 8762
|
| ___________________________________________________________________________________________________ |
| Number: 201106132 |
Principal Investigator: Margenthaler, Julie |
| Title: Photoacoustic/Optical/Ultrasonic Images of Sentinel Lymph Nodes: A Pilot Study to Assess Feasibility |
| Description: The primary goal of this research study is to see if we can use photoacoustic imaging in breast cancer patients to identify sentinel lymph nodes, which are the first group of lymph nodes reached by cancer if it is
metastasizing (spread of the cancer cells to other parts of the body). Lymph nodes ar...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201011825 |
Principal Investigator: Monsees, Barbara |
| Title: Monitoring of Breast Neoadjuvant Therapy by Thermoacoustic and Photoacoustic Tomography |
| ___________________________________________________________________________________________________ |
| Number: 201209143 |
Principal Investigator: Cyr, Amy |
| Title: A prospective, randomized trial of sentinel lymph node biopsy versus no additional staging in patients with T1-T2 invasive breast cancer and negative axillary ultrasound |
| Description: The purpose of this study is to determine if axillary ultrasound can be used instead of sentinel lymph node biopsy to detect spread of the breast cancer to the lymph nodes under the arm without compromising patient treatments or outcomes. The obvious advantage of using axillary ultrasound instead of...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201104345 |
Principal Investigator: Allred, D. Craig |
| Title: Repository of Archival Human Breast Tissue (RAHBT) |
| ___________________________________________________________________________________________________ |
| Number: 201101831 |
Principal Investigator: Goodman, Melody |
| Title: Mammography Outreach Patient Registry |
| ___________________________________________________________________________________________________ |
| Number: 201105088 |
Principal Investigator: Stockerl-Goldstein, Keith |
| Title: Multi-Institutional Breast Cancer Outcomes Project within the National comprehensive Cancer Network |
| ___________________________________________________________________________________________________ |
| Number: 201302004 |
Principal Investigator: Tenenbaum, Marissa |
| Title: A Prospective Randomized Trial to Assess Perfusion and Patient Satisfaction in Nipple-Areola Mastectomy with Immediate Reconstruction |
| ___________________________________________________________________________________________________ |
| Number: 201203103 |
Principal Investigator: Kaphingst, Kimberly |
| Title: Communication Preferences for Genome Sequencing Results in Breast Cancer Patients |
| ___________________________________________________________________________________________________ |
| Number: 201205055 |
Principal Investigator: Wildes, Tanya |
| Title: Clinical and Biological Predictors of Chemotherapy Toxicity in Older Adults |
| Description: The goal of this project is to develop questions and blood tests to understand the individual’s risk of side effects that can be used in daily oncology practice. This information will make it possible to weigh the risks and benefits of cancer treatment based on factors other than chronological age. ...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201207041 |
Principal Investigator: Wagner-Johnston, Nina |
| Title: Validity of the EORTC QLQ-CIPN20 Instrument: An evaluation of the questionnaire in patients with breast cancer undergoing neoadjuvant or adjuvant chemotherapy (doxorubicin/cyclophosphamide) without known risk for development of chemotherapy-induced peripheral neuropathy (CIPN)
|
| Description: The purpose of this research study is to evaluate a questionnaire called the EORTC QLQ-CIPN20, which was developed to assess peripheral neuropathy caused by chemotherapy. The goal of asking you to complete this questionnaire throughout your treatment is to make sure that the questionnaire does not ...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201209135A |
Principal Investigator: Ma, Cynthia |
| Title: A Phase II Study of Neratinib in Metastatic HER2 Non-amplified but HER2 Mutant Breast Cancer
ANCILLARY BANKING PROTOCOL ENTRY |
| ___________________________________________________________________________________________________ |
| Number: 201106250 |
Principal Investigator: Wickline, Samuel |
| Title: Angiogenic Screening for Nanoparticle Based Imaging of Breast Carcinoma |
| ___________________________________________________________________________________________________ |
| Number: 201102502 |
Principal Investigator: Piwnica-Worms, Helen |
| Title: Human-in-Mouse Models of Breast Cancer |
| ___________________________________________________________________________________________________ |
| Number: 201102355 |
Principal Investigator: Ellis, Matthew |
| Title: Cyclin-D1 as a Marker for Responsiveness of Advanced Breast Cancer to Estradiol Therapy in Post-Menopausal Women with Hormone Receptor Positive and Aromatase Inhibitor Resistant Breast Cancer |
| ___________________________________________________________________________________________________ |
| Number: 201102244 |
Principal Investigator: Ellis, Matthew |
| Title: Longitudinal Cancer Genome Profiling Using Sequential Tissue Biopsies in Patients with Breast Cancer
|
| ___________________________________________________________________________________________________ |
| Number: 201101961 |
Principal Investigator: Aft, Rebecca |
| Title: Effect of Neoadjuvant Chemotherapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells |
| ___________________________________________________________________________________________________ |
| Number: 201208003 |
Principal Investigator: Colditz, Graham |
| Title: ENERGY Trial Formalin Fixed Paraffin-Embedded Tissue Collection |
| ___________________________________________________________________________________________________ |
| Number: 201107282 |
Principal Investigator: Colditz, Graham |
| Title: Intermediate Markers of Breast Cancer Risk |
| ___________________________________________________________________________________________________ |
| Number: 201212038 |
Principal Investigator: Khwaja, Shariq |
| Title: Breast Cancer in Women under 40 years: Evaluation of Patient-, Tumor-, and Treatment-related Prognostic Factors |
| ___________________________________________________________________________________________________ |
| Number: 201210126 |
Principal Investigator: Cyr, Amy |
| Title: Identification of Invasive Lobular Carcinoma Sentinel Lymph Node Metastases by Immunohistochemistry |
| ___________________________________________________________________________________________________ |
| Number: 201210113 |
Principal Investigator: Roach, Michael |
| Title: Brachial plexus toxicity with adjuvant comprehensive radiation therapy for breast cancer |
| ___________________________________________________________________________________________________ |
| Number: 201201138 |
Principal Investigator: Appleton, Catherine |
| Title: Performance audit of Breast MR in an Academic Practice |
| ___________________________________________________________________________________________________ |
| Number: 201110127 |
Principal Investigator: Bradbury, Christopher |
| Title: Evaluation of Comprehensive Radiation Therapy Effects on Complications Related to Post-Mastectomy Tissue Expander Based Reconstruction in Patients with Breast Cancer |
| ___________________________________________________________________________________________________ |
| Number: 201108305 |
Principal Investigator: Olsen, Margaret |
| Title: Immediate vs. Delayed Reconstruction and Breast Cancer Surgery Complications |
| ___________________________________________________________________________________________________ |
| Number: 201102494 |
Principal Investigator: Olsen, Margaret |
| Title: Immediate vs. Delayed Reconstruction and Breast Cancer Surgery Complicaitons 2. Chart Validation of ICD-9 Codes |
| ___________________________________________________________________________________________________ |
| Number: 201102027 |
Principal Investigator: Fowler, Amy |
| Title: Prognostic Factors and Clinical Outcomes for Breast Cancer Patients with Liver Metastases Treated with Locoregional Therapy |
| ___________________________________________________________________________________________________ |
| Number: 201110267 |
Principal Investigator: Gillanders, William |
| Title: A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Mammaglobin-A DNA Vaccine in Breast Cancer Patients with Metastatic Disease |
| Description: The overall goal of this study is to find out about the safety of injecting the gene (DNA) for mammaglobin-A into patients with breast cancer. DNA is material that contains the information needed to produce many substances in the body. The DNA used in this study was purified from bacteria and contai...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201108327 |
Principal Investigator: Wang-Gillam, Andrea |
| Title: Phase I Study of Erlotinib and Temsirolimus in Resistant Solid Malignancies |
| Description: The purpose of this study is to determine the maximum tolerated dose and side effects of the combination of two drugs, temsirolimus and erlotinib, used to treat solid tumor cancers. Temsirolimus is approved by the Food and Drug Administration (FDA) for treatment of renal cancer and is considered inv...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201107068 |
Principal Investigator: Lockhart, A. Craig |
| Title: Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients with Varying Degrees of Hepatic Impairment |
| Description: The purpose of this study is to determine if Cabazitaxel is a safe treatment for patients with advanced cancers of different types who also have different levels of liver dysfunction. The highest safe dose of cabazitaxel (the maximum tolerated dose, or MTD) that can be given to patients with your le...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201102468 |
Principal Investigator: Lockhart, A. Craig |
| Title: An Open-Label Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 When Administered as a Single Agent in Patients With
Advanced or Metastatic Solid Tumors |
| Description: There are two parts to this research study. The purpose of Part 1 is to find out the highest safe dose of the investigational drug CEP-9722. “Investigational” means that the study drug has not been approved by the United States Food & Drug Administration (F.D.A). Part 2 of the study is to find out m...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201102462 |
Principal Investigator: Lockhart, A. Craig |
| Title: A Phase 1b, Multi-Center, Open Label, Uncontrolled, Serial Cohort, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Daily Oral Doses of ZSTK474 in Subjects with Advanced Solid Malignancies |
| Description: The main purpose of this study is to find out if the drug ZSTK474 is safe in people who have advanced cancers.
ZSTK474 is an investigational (experimental) drug. This means it has not been approved by the Food and Drug Administration (FDA). It is not currently on the market in any country. This stu...MORE |
| ___________________________________________________________________________________________________ |